.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Oncologists frequently utilize 5-fluorouracil (5-FU) to treat various solid tumors because of its efficacy. However, its clinical application remains limited by significant side effects, most notably hepatotoxicity. Recent studies indicate that Boldine for 5-FU hepatotoxicity could serve as a promising protective agent by modulating antioxidant pathways. Therefore, researchers have evaluated the potential of boldine, a natural aporphine alkaloid, in mitigating this chemotherapy-induced liver injury.
Boldine demonstrates remarkable antioxidant and anti-inflammatory properties. In addition, this compound specifically activates the Nrf2/ARE signaling pathway in liver tissues. This activation subsequently boosts the expression of essential antioxidant genes like NQO1 and HO-1. Furthermore, boldine treatment effectively lowers serum transaminases, which typically spike during acute hepatocellular injury. Consequently, boldine helps maintain the redox balance within the liver cells.
Moreover, 5-FU administration usually suppresses Nrf2 mRNA expression while increasing markers of inflammation such as NF-κB and ASK1. Conversely, boldine therapy reverses these biochemical alterations. In addition, it enhances dihydropyrimidine dehydrogenase expression, an enzyme critical for the metabolism of 5-FU. As a result, these combined actions ameliorate histopathological damage and restore overall hepatic function. Overall, these findings highlight boldine as a potential adjuvant to reduce the toxic burden of chemotherapy.
Boldine protects the liver by activating the Nrf2/ARE signaling pathway. This process increases the production of antioxidant enzymes and reduces the oxidative stress and inflammation caused by 5-fluorouracil. Furthermore, it helps regulate the metabolism of the drug itself.
In studies, boldine effectively reduces elevated serum transaminases like ALT and AST. It also suppresses inflammatory markers such as NF-κB and increases the expression of cytoprotective antioxidant genes like HO-1 and NQO1.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study shows boldine protects against 5-FU-induced liver injury by activating Nrf2/ARE pathways and reducing oxidative stress and inflammation....
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
